Table 3 TAM and DC subpopulations in TIME identified by scRNA-seq
From: Unravelling immune microenvironment features underlying tumor progression in the single-cell era
Tumor type | Sample | Subsets | Key findings | Ref |
|---|---|---|---|---|
Colorectal cancer | Tumor and adjacent tissue precancerous tissue | TAM (SPP1+, CXCL5+, C1QC+, and CD55+) | These subgroups have both pro-inflammatory and anti-inflammatory effects | [73] |
Clear Cell Renal Carcinoma | Tumor and adjacent tissues | TAM (C1Q+TREM2+APOE+) | The group of TAM leads to tumor recurrence | [160] |
Ovarian cancer | Tumor | TAM(NR1H2, IRF8, and CD274) | This macrophage cluster has anti-tumor effects | [117] |
Hepatocellular carcinoma | Tumor and adjacent tissues and ascites and peripheral blood, and lymph nodes | CD74+ TAM | The CD74+TAM increases the infiltration of CD8+ CTL and enhances effector functions in HCC | [161] |
Prostate Cancer | Tumor and adjacent tissues | TAM (SLC40A1, PLAC8, and FCN1) | The group of TAMs has a poor prognosis in patients | [162] |
Hepatocellular carcinoma | Tumor and adjacent tissues and ascites and peripheral blood, and lymph nodes | LAMP3+ DC | The group of DCs has the potential to migrate from tumors to LNs | [94] |
Nasopharyngeal carcinoma | Tumor | CLEC9A+ DC | This cell population is expected to be a new therapeutic target | [85] |